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Abstract 
 
Objective: The epidemiology of polyautoimmunity in Sjögren's syndrome (secondary Sjögren's syndrome - sSS) is not well-defined and was not 
investigated before using a systematic approach. We conducted a systematic review of the epidemiology of sSS associated with rheumatoid 
arthritis (RA), systemic lupus erythematosus (SLE), scleroderma and myositis, assessing the prevalence rates (PRs) and clinical and serological 
features of sSS.  
Methods: A systematic literature search of PubMed and Embase databases (updated to March 2016) was performed to identify all published 
data on prevalence rate, demographic profile, clinical manifestations, laboratory features and causes of death associated with sSS. The 
prevalence rates of pSS were summarised with PRs and 95% CIs.  
Results: The literature search identified 1639 citations, out of which 42 fulfilled the inclusion criteria. Only 19 studies had moderate to good 
quality and were selected for the meta-analysis. According to a random-effects model, the pooled PR for sSS associated with RA was 19.5% 
(95% CI 11.2 to 27.8) and the pooled PR for sSS associated with SLE was 13.96% (95% CI 8.88 to 19.04). The female/male ratio of sSS in the 
RA population was 14.7 (95% CI 7.09 to 256) and 16.82 (95% CI 1.22 to 32.4) in the SLE population.  
Conclusion: Prevalence rates of sSS vary widely in different populations. Both meta-analyses conducted in the RA and SLE populations were 
characterised by a high degree of study heterogeneity. The results of this meta-analysis highlighted the need for better quality population studies. 
 
Keywords: secondary Sjögren’s syndrome, polyautoimmunity in Sjögren’s syndrome, prevalence, sex ratio, systematic review, meta-analysis.  
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Introduction 
Sjögren’s syndrome (SS) is a chronic systemic autoimmune disorder, which is associated in the majority of cases with lymphocytic infiltration of 
exocrine glands and epithelium, feature that is considered the histological hallmark of the disease (1). The T cell mediated attack on salivary and 
lacrimal glands results in chronic inflammation, which is considered in the majority of cases the leading cause to glandular atrophy and deficient 
glandular function (2). Although, the temporal relationship between the presence of glandular inflammatory infiltrate and atrophic/fibrotic 
changes associated with ageing and/or disease progression is difficult to appreciate, the minor salivary gland biopsy have their role in the 
stratification and prognostication of patients with SS (3). 
SS is characterised clinically by symptoms of dry mouth (xerostomia) and dry eyes (xerophthalmia), known as sicca symptoms. SS can progress 
to affect many organ systems (lung, kidney, gastro-intestinal tract, skin, musculoskeletal, and peripheral and rarely central nervous system), and 
as a result, other clinical manifestations ranging from mild to more severe disease may occur, including: arthralgias, vasculitis, peripheral 
neuropathy, renal failure and interstitial lung disease (4). In addition, SS is associated with increased risk of lymphoma (5).  
SS can occur either alone as primary SS (pSS) or in association with another well-defined autoimmune condition, such as systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), or dermatomyositis (DM), in which case it is known as secondary SS 
(sSS) (6). Although, some researchers prefer to use the term of “polyautoimmunity” associated with SS rather than sSS (7, 8), for the purpose of 
our systematic review, we used the previously accepted terminology of sSS, which enabled us to identify all the relevant papers. In addition, the 
term “polyautoimmunity” refers to clusters of autoimmune conditions, which may include or not autoimmune rheumatic diseases (8). Previous 
papers focused predominantly on prevalence studies and distinct immunologic differences between different sSS subtypes, rather than 
differences in clinical presentations or controversies regarding the patients’ diagnosis.  
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The diagnosis of SS cannot be made on a single test or symptom. The variability in presentation of SS has led to a difficulty over the years in 
establishing universally accepted classification criteria. Therefore, there has been a variation in prevalence estimates in the few epidemiological 
studies that have been documented, as they used different classification criteria (1, 9). Although the clinical features of pSS are relatively well-
researched in large epidemiological studies (10, 11), there are very few studies looking at the epidemiology and clinical and serological features 
of sSS.  The authors felt that a systematic review of the epidemiology of sSS was needed in order to establish any significant differences in the 
presentation of sSS according to the background rheumatic condition of patients that might have impact on their long-term management.  
 
Over the last few decades, diagnostic criteria have varied according to different national and international groups. At present, the most widely 
accepted and cited criteria are the American-European consensus group classification criteria (AECG), which were published in 2002 as a 
revision from the original European Study group criteria described in 1996 (2, 12). Interestingly, the presence of anti-Ro/La antibodies has not 
been included as a mandatory classification criteria for sSS, since it was not shown to be significant in previous analysis (13). New classification 
criteria for SS were recently developed and validated (14, 15). Although, they do not introduce any significant changes, they have been validated 
in three international patient cohorts, and emphasised the role of expert opinion in diagnosing SS.  
 
Methodology 
 
We performed a PUBMED and EMBASE search for articles involving humans only, published between 1984 and 2016. The MESH terms used 
were: secondary Sjögren’s, epidemiology of Sjögren's syndrome, secondary Sjögren’s and systemic lupus erythematosus, secondary Sjögren’s 
and rheumatoid arthritis, secondary Sjögren’s and systemic sclerosis/scleroderma/CREST syndrome, and secondary Sjögren’s and myositis. As 
criteria for study selection, we considered all the studies on the epidemiology, diagnosis and follow-up of patients with sSS.  We excluded 
editorials, commentaries, animal studies, questionnaire studies, case reports, case-series, and studies of treatment (Figure 1). 
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We extracted data on prevalence, demographic profile, clinical manifestations, laboratory features, underlying autoimmune diseases and causes 
of death from the selected articles, where available, and organised them in tables.  
 
Studies were grouped according to the following patient categories: 1). secondary Sjögren’s and systemic lupus erythematosus, 2). secondary 
Sjögren’s and rheumatoid arthritis, 3). secondary Sjögren’s and scleroderma and 4). secondary Sjögren’s and myositis. We present our results 
data under the following headings: prevalence and demographics of secondary Sjögren’s syndrome in different autoimmune diseases, clinical 
and laboratory features of Sjögren’s syndrome in different autoimmune diseases, and morbidity and mortality associated with secondary 
Sjögren’s syndrome. Prevalence rates were calculated using 95% CI.  Pooled prevalence rates and sex ratios were calculated using a random 
effects model (based on the Q and I
2
 tests of heterogeneity among studies). 
 
Results: 
 
The initial research yielded 1639 articles, which were screened for titles and abstracts, of which 37 were selected for review based on the 
inclusion and exclusion criteria mentioned above (the detailed process of paper selection is detailed in Figure 1). Following an additional manual 
search of other relevant articles, we identified 42 full papers and abstracts, which met the inclusion criteria and were analysed further.  
We appreciate a risk of reporting bias for the majority of studies as they addressed different populations and used different classification criteria 
for sSS. The study quality was weighted as poor, moderate and good based on the following criteria: number of patients, the use of established  
SS classification criteria, data about patient sex, ethnicity and disease duration, inclusion of lip biopsy in the classification criteria (especially as 
the serology is likely to be positive in lupus patients, irrespective of concomitant SS). The assessment of study quality was reviewed 
independently by HA and CC. There was an 82% consensus. The studies in which case the consensus was not reached, were further evaluated by 
the third author (EJ) and graded based on the assessment made by two of the three authors. The details of study quality assessment were included 
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in Table 1. Based on this selection, 9 SLE studies and 11 RA studies assessed as having moderate to good quality were included in the final 
meta-analysis.  
 
Prevalence and demographics of SS associated with different autoimmune diseases 
 
Our search identified 40 worldwide studies, which evaluated the prevalence of sSS in patients with RA, SLE, SSc and myositis. The study 
designs included were retrospective, cross-sectional and prospective (Table 2). The number of patients used in each study ranged from 6 to 2694. 
 
Criteria 
Different criteria were used across the different studies to classify patients as having sSS, including AECG (14), ECC (7), Japanese classification 
criteria (1), and other criteria (9). Nine studies did not specify the classification criteria they used.  
 
Prevalence 
We found 18 studies which looked at the prevalence of RA-sSS (between 1987-2013) (16-33), 13 for SLE-sSS (1998-2015) (34-46), 6 for SSc-
sSS (1983-2013) (47-52) and 3 for myositis-sSS (2011-2014) (53-55). The prevalence ranged from 3.6%-55% for RA-sSS, 5%-22% SLE-sSS, 
14%-60% SSc-sSS and 10-23% for myositis-sSS. In the RA-sSS studies three of the highest reported prevalence all came from studies carried 
out in Greece on Greek patients (31- 39.8%)(18, 20, 23).  
 
Gender 
Not all studies reported the gender of the patients, however in the 15 that did, females were predominantly affected (82%-100%). Less than half 
of all studies (17/37) highlighted the ethnicity of the patients included in the study. 
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Age 
In five studies (36, 39, 42, 44, 45) SLE-sSS patients were reported to be significantly older when compared to those with SLE only (48.3 vs. 
36.1, p<0.001; 41.3 vs. 35.8, p=0.003; 50.8 vs. 43.6, p=0.01; 41 vs. 35 p=0.03, and 49.5 vs. 41.4 p<0.001). This was not found to be the case for 
RA-sSS patients when compared to RA patients as reported by two studies (63.0 vs. 59.2, p=0.33 and 66.36 vs. 62.40, p=NS) (21, 28). There 
was also no significant difference in age between SSc vs. SSc-sSS patients reported in three studies (56 vs. 54, p=NS; 50.2 vs. 55, p=0.18, and 
48.3 vs. 50.5 p=NS) (50-52).   
 
Disease duration 
Disease duration was reported in 26/40 studies and varied across all studies ranging from 4 months -12 years for RA-sSS (16, 20-23, 25, 27-29, 
32, 33), 3-46 years SLE-sSS (34-37, 39, 41, 42, 44), 7-8 years SSc-sSS (47, 50-52), and 67 months to 20 years for myositis-sSS (53-55). 
 
Only the RA-sSS studies looked into the relationship between disease duration and sSS incidence rate. There were conflicting reports with 
regard to whether RA disease duration plays any role in the reported occurrence rate of sSS. Two studies found that the cumulative prevalence of 
sSS did increase with RA duration (19, 29). This finding however, was not supported by four other studies (21, 22, 25, 28). 
 
 
Clinical and laboratory features of sSS associated with different autoimmune diseases: 
 
We identified 17 studies assessing the clinical and laboratory features of sSS (Tables 3-4). The reported clinical features varied depending on 
which condition associated with sSS was being looked at.  
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SLE-sSS 
Of the seven studies (36, 37, 39, 42, 44-46) assessing clinical features of SLE-sSS, the majority reported data on the presence of renal 
involvement and central nervous system (CNS) involvement. Renal involvement was found to be significantly reduced in SLE-sSS patients 
across five studies (36, 37, 39, 44, 45), while thyroiditis was found to be significantly higher. CNS involvement prevalence, although reduced in 
SLE-sSS patients, was not significant in any of the three studies. Only one study reported no cases of  lymphoma in their cohort of 26 SLE-sSS 
patients (36), although they reported 8 cases of lymphoma in their pSS comparative group (N=86) . 
Regarding serological markers, only anti-Ro/SSA and anti-La/SSB antibodies were significantly raised in SLE-sSS compared to SLE patients in 
five studies (36, 37, 39, 42, 44). Anti-dsDNA was higher in SLE patients and this reached significance in four studies (37, 39, 42, 44). 
Thrombocytopenia was lower in SLE-sSS patients, although this was only significant in two studies (36, 45).    
 
Koskenmies et al. reported that sSS was most commonly observed in patients with subacute cutaneous lupus erythematosus (SCLE) and SLE 
than in patients with discoid lupus erythematosus (16.4% vs. 22.1% vs. 2.3%, p<0.001) (43) . 
 
RA-sSS 
Five studies addressed clinical features of RA-sSS patients (21, 22, 25, 27, 28). The majority reported data on joint swelling, tender joints and 
disease activity score assessing 28 joints (DAS 28 score). Half the studies reported that tender joints were significantly higher in RA-sSS patients 
compared to RA patients (22, 27), while the other half reported no significant difference (21, 28). Only one reported study looked at other 
clinical features including lymphadenopathy, thyroiditis, lung, renal and CNS involvement (27). 
 
Laboratory analysis was mainly focused on RF, anti-CCP, CRP and ESR levels. There was inconsistency concerning the reported RF levels. 
Three studies (22, 25, 27) reported higher levels of RF in RA-sSS patients, one being significant, while the opposite was found in two other 
studies, although not significant (21, 28). 
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SSc-sSS 
Four studies (47, 50-52) reported data about lung involvement, mainly pulmonary fibrosis (PF) and pulmonary arterial hypertension (PAH).  PF 
occurred significantly less frequently in SSc-sSS patients. Only one study reported lower occurrence of PAH in SSc-sSS, which was significant 
(52). 
 
The majority of studies looked at anti-topoisomerase 1 antibodies and anti-centromere (ACA) levels. ACA levels were significantly higher in 
SSc-sSS patients across all three studies (50-52). However, there was discrepancy regarding the prevalence of anti-topoisomerase 1 antibodies.  
 
Myositis-sSS 
 
In one study, all six patients with both diseases presented with a pattern of muscle weakness typical of IBM (53). Five IBM-sSS patients were 
treated with prednisolone and methotrexate, four of whom had temporary symptomatic improvement (6-24 months). This was a far greater 
response in comparison to the IBM only group in whom only 27% had a transient response to treatment. 
 
 
Immunogenetics 
 
SLE-sSS 
Immunogenetic analysis was carried out in two studies. In one study there was no significant difference between the SLE and SLE-sSS patients 
when looking at the HLA alleles (42). However, in another study, the HLA associations distinguished the SLE group from those with SLE-sSS. 
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Those with SLE  were found to have increased phenotype and allele frequencies for DRB1*1501 (p=0.020 and p=0.015, respectively) and 
DQB1*0602 (both p<0.001) that was significant (36). 
 
Myositis-sSS 
In the study mentioned above (53), all six patients carried the HLA-DRB1*0301 allele or its equivalent HLA-DR3 serological specificity. They 
also carried either all or some of the major markers of the 8.1 MHC ancestral haplotype. This allele was also reported to be highly prevalent 
among the Norwegian patients included in another study (25%), which found a prevalence of rheumatic disorders of 24%, which is twice as high 
as previously reported (55). 
 
Morbidity and mortality associated with sSS 
 
In a few RA studies other aspects of the disease including its effect on quality of life and its involvement in haematological malignancies was 
studied.   
 
Health status 
 
RA-sSS 
In three of the five studies measuring health status there was no difference in the DAS-28 mean scores in RA-sSS compared to RA patients (21, 
25, 28). In two other studies (22, 27) however, a higher DAS-28 score was found in RA-sSS patients, compared to RA patients (6.44 vs. 5.96, 
p=0.02 and 5.08 vs. 4.20, p=<0.001, respectively).   
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One study (22) looked at other health status measures including pain visual analogue scale (VAS) scale, fatigue VAS and Modified Health 
Assessment Questionnaire (M-HAQ), and found that the RA-sSS patients scored significantly higher in all three tests in comparison to RA 
patients (43.1 vs. 32.9, p =<0.01; 49.8 vs. 39.7, p=0.03, and 1.75 vs. 1.55, p=0.04, respectively). Another study (28) looked at both M-HAQ and 
pain VAS tests and reported similar findings in both groups of patients (0.84 vs. 0.81, p=0.7, and 35.9 vs. 42.4, p=0.3, respectively). 
 
 
 
Haematological malignancy and mortality 
 
SLE-sSS 
Nossent et al. (45)  reported a significantly reduced overall mortality in patients with SLE-sSS compared to SLE patients (4% vs. 13.5%, 
p=0.01). In two studies in which patients where followed up for three years and 8 years respectively, none of the patients developed lymphoma 
(36, 45). 
 
Martens et al. looked at the survival of sSS patients in a population-based sample in Minnesota, USA between 1976 and 1992. Of the 74 cases 
24 (33%) had sSS and 50 (67) had pSS. It found that when compared with the general population, SS patients had increased mortality (p=0.04). 
Furthermore, when studied separately, the mortality was increased in sSS compared to pSS patients (p=<0.005), with the majority of sSS 
patients having associated RA (p= 0.86) (56). 
 
RA-sSS 
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With regard to haematological malignancies, studies have reported increased incidence of non-Hodgkin’s lymphoma (NHL) in RA-sSS patients. 
A Finnish study carried out by Kauppi et al. compared the incidence of NHL in 9,469 RA patients and 709 sSS patients.  This study found the 
incidence of NHL to be almost two-fold in patients with RA-sSS (8.7, CI=4.3-1.6) compared to RA patients (4.5, CI=1.5-11) (56).  
 
SSc-sSS 
Baldini et al. described a new clinical phenotype of “ACA-positive limited scleroderma/SS overlap syndrome”, which in their retrospective 
study was characterised by a benign SSc clinical course but at a high risk of non-Hodgkin's lymphoma (57). 
 
 
 
Meta- analysis of prevalence rates and sex ratios of sSS associated with SLE and RA 
 
The results of the meta-analysis revealed a pooled prevalence of 13.96% (95% CI 8.88 to 19.04) in the SLE population and 19.5% (95% CI 11.2 
to 27.8) in the RA population. The statistical analysis of the selected studies revealed a high degree of heterogeneity as expected (I2 = 99.98 for 
the SLE studies and 99.92 for the RA studies; therefore, we used a random effect statistical model for calculating the pooled prevalence). The 
results of the meta-analysis are presented in Figures 2 and 3.   
 
We also analysed the sex ratio of sSS patients in the SLE and RA populations, which revealed a clear predominance of female patients (four RA 
studies reported that all their sSS/RA patients were females). The female: male ratios were 16.82 (95% CI 1.22 to 32.4) for the SLE-sSS patients 
and 14.7 (95% CI 7.09 to 256) for the RA-sSS population.  
 
Discussions 
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Secondary SS is characterised by a heterogeneity of clinical manifestations, serological markers and symptoms, which are influenced by 
patients’ underlying pathology. Unfortunately, large prospective studies comparing patients with sSS associated with different autoimmune 
rheumatic diseases are lacking. Previous studies were interested in comparing the clinical and laboratory features of an autoimmune disease 
alone or associated with sSS (as the majority of the studies included in this systematic review), or aimed to compare the epidemiology of pSS vs. 
sSS (this was beyond the scope of our systematic analysis). Other papers explored the communality of serological abnormalities and shared 
clinical picture in distinct autoimmune rheumatic diseases, such as RA and pSS (58), or advocated that the association of SS with multiple 
autoimmune diseases, is better described as “polyautoimmunity” (7), as discussed in introduction. However, this terminology is not particularly 
exact in relation to the presence of clinical and serological features of SS in the context of rheumatic conditions (which is the focus of this 
review), as it also refers to associations of SS with other autoimmune diseases (8).   
 
There is evidence of a great degree of heterogeneity within all these populations; although previous research established that pSS is associated 
with a different disease phenotype compared to sSS: e.g. pSS patients had a higher frequency of parotid gland enlargement and Ro and La 
antibody positivity (59), or had significantly higher levels of IL-2 and IL-6 in their saliva (60). An old study also suggested that extraglandular 
features are more common in pSS compared to sSS (61).   
 
Our study could not address any controversies regarding the accuracy of patients’ diagnosis (e.g. many clinicians’ might decide based on their 
expert opinion to diagnose a patient as having RA associated with SS rather than symmetrical polyarthritis in the context of primary SS). In 
addition, our systematic review does not imply that patients with sSS associated with different ARDs have similar features (e.g. SLE and SS 
patients might have similar clinical presentation, which is not the case with patients with SS associated with SD or myositis). Even if only 
moderate-good quality studies were included in the meta-analysis, the studies with poor quality were also detailed in the paper. In addition, our 
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systematic review also reported on papers relevant for the article theme, even if not selected by our systematic approach, such as papers referring 
to patients defined as having overlapping syndromes rather than sSS (57) or which contained no data about sSS prevalence (62). 
 
Our analysis revealed that sSS is more common in women, irrespective of the underlying autoimmune disease. The confidence intervals of sex 
ratios in the SLE and RA patients with associated sSS reflected again the high heterogeneity of the studies and the inclusion of studies, which 
reported the presence of sSS exclusively in the female population.  
 
Despite the effort to define the sSS patient population better, clinicians are still unable to answer practical questions regarding the difference in 
the long term outcome of sSS associated with an autoimmune disease compared to having only an autoimmune disease, or regarding the best 
way to stratify these patients to enable the choice of the most suitable therapeutic options. It is recognized that sSS is characterised by significant 
amount of variability in clinical presentation, which is influenced by the concomitant autoimmune disease; however, different studies reported 
various epidemiological features in the context of similar background autoimmune disease. This variation can be in part explained by the SS 
classification criteria applied, as well as patient selection criteria, their ethnicity or genetic background, and possible reporting bias (45, 63). Our 
results show that Raynaud’s phenomenon, thyroiditis and Ro, La antibody positivity seemed to be more frequent in SLE-sSS patients compared 
to SLE group, while renal involvement and presence of dsDNA, and anti Sm antibodies were more common in the latter group. A less clearly 
defined trend was identified in the case of thrombocytopaenia and lung involvement, while the CNS involvement was reported in only one study 
as more frequent in the SLE-sSS group.  
 
The number of tender and swollen joints was more commonly reported in the RA compared to RA-sSS group, however, the RA-sSS group had 
more CNS involvement, Raynaud’s phenomenon, thrombocytopaenia and hypergammaglobulinaemia.  
 
Page 15 of 71
Scandinavian Journal of Rheumatology
Scandinavian Journal of Rheumatology
For Peer Review
In the scleroderma and myositis groups, the main differences were seen in the positivity of antibodies (the disease characteristic ones being more 
prevalent in their corresponding group). However, as there was no significant overlap between the clinical features of these autoimmune 
conditions, and the quality of the studies was poor, no assumptions can be made about the difference in the clinical presentation of SSc-sSS 
made for patients’ clinical phenotype, apart from additional symptoms of dryness, and a possible subset of patients with overlap syndrome with 
milder disease presentation (57).  
Importantly, studies of both SLE and SSc populations hinted at the possibility that these patients have the highest risk of lymphoma of all the 
autoimmune disease groups (44, 57).  
 
Our systematic review included mainly prevalence studies (as the large population studies were lacking) and reported prevalence rather than 
incidence figures (as sSS is reported in patient groups rather than general population, and the appreciation of the newly diagnosed cases per year 
necessitates long prospective studies not available in the literature). The quality of the studies included in the analysis was poor to moderate 
because of the following reasons: significant heterogeneity of patient inclusion criteria (12 studies did not use validated classification criteria and 
were excluded from the final analysis); variable number of patients included (from 6 to 2694); different proportion of patients classified as 
having SS based on salivary gland biopsy (14 studies included the biopsy as a classification criteria for all the sSS patients, and 5 studies for a 
variable proportion of patients); limited geographic areas (only one study evaluated patients from two different countries), and difficulty to 
extrapolate data to other populations (there were no studies from South America, Africa or Oceania).  There was also evidence of significant 
statistical heterogeneity in our meta-analysis of sSS prevalence in SLE and RA patients, probably due to both, clinical and methodological 
differences between studies.  
 
The authors identified an unmet need for a consensus regarding the diagnostic/classification criteria for sSS in the context of different underlying 
autoimmune diseases, especially in the group of SLE/sSS, which is characterised by shared clinical and serological features that make the 
diagnosis difficult in the absence of a positive salivary gland biopsy.   
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In conclusion, this is the first systematic review and meta-analysis of the epidemiology of sSS, which aimed to evaluate the characteristics of this 
heterogeneous population. Because of the lack of prospective longitudinal data in large population studies, there are still unanswered questions 
related to the malignancy risk of these patients or their clinical and laboratory features in less common autoimmune diseases. 
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Figure legends: 
Figure 1: Flowchart of study selection. 
Figure 2: Meta-analysis of the prevalence of sSS in SLE patients. 
Figure 3: Meta-analysis of the prevalence of sSS in RA patients. 
 
 
 
Table 1: Studies reporting the disease duration and relationship with the sSS prevalence in RA patients. 
 
 
Study Disease duration  Relation between 
prevalence of sSS and RA 
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disease duration 
Uhlig et al.,1999 12.2 years None 
Antero et al., 2011 10.2 +/- 7 years None 
Abdelghani, 2014 15.6 years None 
Haga et al.,2012 10.63 years None 
Carmona et al.,2003 - Prevalence at 10 years 17%, 
and 25% after 30 years  
Young et al.,2000 10 years Prevalence at 1 year 4%, and 
12% after 10 years 
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Table 2: Studies included in the systematic review 
 
 Study 
design 
Country 
 
Number 
of  
patients  
Criteria 
used 
Number 
of sSS 
cases (%) 
Ethnicity Female/male 
(n) 
 
Disease duration 
(years/months) 
Salivary gland 
biopsy  
Study quality 
Systemic lupus erythematosus 
Nossent et al, 
1998 
P Norway/ 
Netherlands 
 
138 ECC N=27 
(19.6%) 
NA 22/5 8 years 12 patients 
tested 
Moderate 
McDonagh et al, 
2000 
R UK 
(London) 
215 ECC N=28 
(13%) 
NA NA 18 years All tested  Moderate 
Gilboe et al, 
2001  
R Norway 
(Oslo) 
81 ECC N=9 
(11%) 
Caucasian 9/0 8 years NA Moderate 
Bowman et al, 
2003   
 
CS 
UK 
(Birmingham) 
96 AECG N=18 
(19%) 
Caucasian 18/0 10.9 years NA Moderate 
Manoussakis et 
al, 2004 
R Greece 
(Athens) 
283 AECG N=26 
(9%) 
Caucasian  26/0 3.5 years  All tested Good 
Szanto et al, 
2006 
R Hungary 
(Debrecen) 
362 AECG N=56 
(15%) 
Caucasian 52/4 8.1 years All tested Good 
Scofield et al, 
2007 
R USA 
(Oklahoma) 
1138 NA N=169 
(15%) 
NA NA NA NA Poor 
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Pan et al, 2008 R China 542 AECG N=35 
(6%) 
Asian Chinese 32/3 3.7 years All tested Good 
Koskenmies et 
al, 2008 
R Finland 
(Helsinki) 
77 NA N=17 
(22%) 
NA NA NA NA Poor 
Baer et al, 
2010 
CS USA 
(Marylands) 
1790 AECG N=259 
(14.5%) 
White= 70.7 
African 
American= 25.5 
Hispanic= 1.9 
Asian= 1.2 
253/6 19.5 years All tested Good 
Maria et al, 2013  CS/R Spain 
(Lugo) 
150 NA N=27 
(18%) 
NA 27/0 NA NA Poor  
Lockshin et al, 
2015 
R USA 600 Other N=28 
(5%) 
NA NA NA NA Poor 
Aggarwal et al, 
2015 
 
L USA 2694 AECG N=548 
(20%) 
Mixed (White, 
Black, 
Hispanic, 
Asian and 
native) 
504/44 20 years NA Good 
Rheumatoid arthritis 
Andonopoulos et 
al, 1987 
P Greece 111 Other N=34 
(31%) 
Greek NA 3.3 - 9.1 years All tested Good 
Martinez Castro 
et al, 1990  
CS Spain 45 NA N=24 
(55%) 
Spanish NA NA All tested Poor 
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Drosos et al, 
1992 
CS Greece/British 
Ioannina/London 
G=108 
B= 107 
Other GK N=43 
(39.8%) 
BS N=17 
(15.9%) 
Greek/British NA NA All tested Moderate 
Uhlig et al, 1999 CS Norway 
(Oslo) 
636 ECCN N=46 
(7%) 
NA NA 12.2 years NA Moderate 
Cimmino et al, 
2000 
CS Italy 
(Northern) 
587 Other N=103 
(17.5%) 
Italian NA 10 years NA Poor 
Mattey et al, 
2000 
CS Spain 
(Lugo) 
179 Other N=22 
(12.3%) 
NA NA NA NA Poor 
Young et al, 
2000  
P UK 732 NA N=54 
(7%) 
NA 46/9 
 
4 - 11 months NA Poor 
Ioannidis et al, 
2002 
CS Greece 
(Ioannina/ 
Athens) 
174 ECC N=57 
(32.7%) 
Greek NA 10.5 years NA Moderate 
Turesson et al, 
2003 
R USA 
(Minnesota) 
609 Other N=58 
(9.5%) 
NA NA 46 years NA Poor 
Carmona et al, 
2003 
CS Spain  788 ECC N=134 
(17%) 
Spanish NA NA NA Moderate 
Fujita et al, 2005  P Japan 
(Tokyo) 
72 Japanese  N=7 
(10%) 
Japanese 7/0 
 
NA NA Poor 
Calgüneri et al, 
2006 
R Turkey 
(Ankara) 
526 NA N=28 
(5.3%) 
NA NA NA NA Poor 
Antero et al, 
2011 
CS Brazil 
(Curitiba) 
82 AECG N=20 
(24.3%) 
NA 18/2 10.2 years All tested Good 
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Kosrirukvongs et 
al, 2012 
CS Thailand 
(Siriraj) 
61 Other N=14 
(22.2%) 
NA NA NA NA Poor 
Haga et al, 2012 CS Denmark 
(Esbjerg) 
307 AECG N=11 
(3.6%) 
NA NA 10.6 years NA Moderate 
Aliko et al, 2010 CS Albania 
(Tirana) 
88 ECC N=13 
(14.8%) 
Albanian NA 9.5 years NA Moderate 
He J et al, 2013 R China 
(Beijing) 
509 AECG N=74 
(14.5%) 
Chinese 64/10 15.10 months 16 patients 
tested 
Good 
Abdelghani, 
2014 
CS France 
(Strasbourg) 
76 AECG N=11 
(14%) 
French NA 15.6 years 9 patients tested Moderate 
Brown et al., 
2015 
CS USA 
(Boston) 
829 AECG N=85 
(10.3%) 
White= 89.4 76/9 16.9 years NA Good 
Systemic sclerosis 
Osial et al, 1983 CS USA 
(Pennsylvania) 
58 
 
Other N=17 
(29%) 
NA 16/1 7.3 years All tested  Good 
Andonopoulos et 
al, 1988 
P Greece 44 
 
Other N=9 
(20.5%) 
 
NA NA NA All tested  Poor 
Drosos et al, 
1991 
CS Greece 23 
 
NA N=14 
(60%) 
 
NA NA NA All tested  Poor 
Avouac et al, 
2006 
P France 
(Paris) 
133 
 
AECG N=19 
(14%) 
NA 16/3 7 years 91 patients 
tested 
Good 
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Legend: CS – cross-sectional study; NA – information not available; P – prospective study; R – retrospective study.  
 
 
 
  
Salliot et al, 2006 R France 
(Paris) 
121 
 
AECG N=27 
(22%) 
 
NA 24/3 7.3 years All tested Good 
Kobak et al, 2013 CS Turkey 
(Izmir) 
118 
 
AECG N=40 
(33.9%) 
 
 
NA 38/2 8.2 years 74 patients 
tested 
Good 
Baldini et al., 
2013 
R Italy (Pisa) 209-
systemic 
sclerosis 
402 
pSS 
Le Roy 
 
AECG 
N=41 NA NA NA NA Moderate 
Myositis 
Rojana-
Udomsart et al, 
2011 
CS Australia 6 AECG N=6 
(12%) 
NA 5/1 
 
20 years NA Poor 
Vancsa et al, 
2010 
CS/R Hungary 169 NA N=9 
(23%) 
NA NA 6 years  NA Poor 
Dobloug et al, 
2014 
CS Norway 100 NA N=10 
(10%) 
NA NA 5.5 years NA Poor  
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Table 3 : Clinical features of patients with sSS 
Disease/Ref Arthritis 
(% 
patients) 
Swollen 
joints 
(% 
patients) 
Tender 
joints 
(% 
patients) 
DAS 28 
score 
Raynaud’
s 
(% 
patients) 
Photo 
sensitivity 
(% 
patients) 
Lymph 
adenopathy 
(% patients) 
Thyroiditis 
(% 
patients) 
Lung 
involvement 
(% 
patients) 
Renal 
involvement 
(% 
patients) 
Nervous 
system 
involvement 
(% patients) 
Lymphoma 
(% patients) 
SLE vs. SLE-sSS patients 
Nossent et al, 
1998 
88 vs. 92 
(p=NS) 
        38 vs. 19 
(p=0.04) 
NPSLE 
18 vs. 19 
(p=NS) 
0% 
Gilboe et al, 
2001 
         19 vs. 0  
(p<0.05) 
  
Manoussakis et 
al, 2004 
51.3 vs. 
76.9 
(p=0.27) 
   43.4 vs. 
80.8  
(p <0.001) 
 
 46.1 vs. 19.2 
 (p=0.004) 
 11.8 vs. 11.5 
(p=0.891) 
55.3 vs. 11.5  
(p=0.005) 
19.7 vs. 11.5 
(p=0.55) 
0% 
Szanto et al, 
2006 
    28 vs. 35.7 
(p=0.396) 
  6 vs. 21.4 
 (p=0.023) 
24 vs. 28.5 
(p=0.59) 
66 vs. 57.1 
(p=0.312) 
36 vs. 25 
(p=0.21) 
 
Scofield et al, 
2007 
       12.7 vs. 29.6 
(p<0.000) 
    
Pan et al, 2008   60.9 vs. 
77.1 
(p=0.056) 
  14.2 vs. 
8.6 
(p=0.45) 
   66.7 vs. 48.6 
(p=0.03) 
9.5 vs. 2.9 
(p=0.35) 
 
Baer et al, 
2010 
73.2 vs. 
81.3 
(p=0.006) 
   49.5 vs. 66 
(p<0.001) 
52.9 vs. 
68.3  
(p=0.001) 
   Proteinuria 
43.1 vs. 29.0 
(p<0.001) 
Haematuria 
30.9 vs. 22.8 
(p=0.008) 
Nephrotic 
syndrome 
20 vs. 8.9 
(p<0.001) 
Psychosis 
3 vs. 6.6 
(p=0.005) 
Seizures 
9.3 vs. 11.6 
(p=0.25) 
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RA vs. RA-sSS patients 
Uhlig et al, 
1999 
100 7.0 vs. 
8.5 
(p=0.17) 
6.1 vs. 9.6 
(p=<0.01) 
4.20 vs. 
5.08 
(p<0.001) 
        
Antero et al, 
2011 
100   3.35 vs. 
2.81 
(p=0.1) 
        
Haga et al, 
2012 
100 0.28 vs. 
0.73  
(p=NS) 
1.1 vs. 2.2 
(p=NS) 
3.1 vs. 2.7   
(p=NS) 
        
He J et al, 2013 100 12.9 vs. 
15.8   
(p<0.05) 
12.1 vs. 
14.5 
(p=0.019) 
5.9 vs. 6.4   
(p=0.009) 
  7.59 vs. 10.8  
(p=0.346) 
27.1 vs. 21.6 
(p=0.320) 
11.7 vs. 44.6  
(p<0.001) 
4.81 vs. 14.9 
(p=0.002) 
0.23 vs. 2.7 
(p=0.010) 
 
Abdelghani et 
al, 2014 
100 3.7 vs. 
3.2 
(p= 0.4) 
6.2 vs. 5.6  
(p=0.4) 
4.13 vs. 
4.05  
(p=0.8) 
1.5 vs. 
27.2 
(p=0.01) 
       
Brown et al., 
2015 
100   4.3 vs. 3.2 
(p=0.01) 
        
SSc vs. SSc-sSS patients 
Osial et al, 1983         Unspecified 
pulmonary 
disease  
64 vs. 65  
9 vs. 12    
Avouac et al, 
2006 
        Lung 
fibrosis  
45 vs. 11 
(p=0.02) 
PAH  
19 vs. 11 
(NS) 
   
Salliot et al, 
2006 
    94.7 vs. 
92.6  
(p= 0.98) 
   Lung 
fibrosis  
29 vs. 11.1 
(p=0.05) 
PAH 15.1 
vs. 7.4 
(p=0.60) 
14.9 vs. 3.7 
(p=0.21) 
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Legend: PAH - pulmonary arterial hypertension; NS - not significant; NPSLE- neuropsychiatric lupus. 
 
  
Kobak et al, 
2013 
        Lung 
fibrosis  
58.9 vs. 30 
(p=0.001) 
PAH 52.6 
vs. 30 
(p=0.001) 
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Table 4: Serological features of patients with sSS 
 
Disease/Ref Ro/ SSA 
antibodies 
(% 
patients) 
La/ SSB 
antibodies 
(% 
patients) 
RF 
(% 
patients/ 
U/mL) 
ANA 
(% 
patients) 
dsDNA 
(% 
patients) 
Anti 
CCP 
(% 
patients) 
Other antibodies/ 
markers 
(% patients) 
ESR/CRP 
(mm/h;  
mg/l) 
Hyper 
gamma 
globulinaemia 
(% patients) 
Thrombo 
Cytopaenia 
(% patients) 
SLE vs. SLE-sSS patients 
Nossent et 
al, 1998 
44 vs. 48 
(p=NS) 
38 vs. 33 
(p=NS) 
 88 vs. 87 
(p=NS) 
71 vs. 53 
(p=NS) 
 Anticardiolipin 
33  vs. 41 (p=NS) 
Anti-Sm 
21 vs. 15 (p=NS) 
Anti-U1 nRNP  
26 vs. 25 (p=NS) 
  9 vs. 26 
(p<0.05) 
Uhlig et al, 
1999 
 
  48.2 U/mL 
vs. 62.2 
U/mL 
(p=0.08) 
    ESR 
18.6 vs.  26.8 
(p<0.01) 
CRP 
11.9 vs. 13.8 
(p=0.33) 
  
Gilboe et al, 
2001 
36 vs. 89 
(p=0.05) 
11 vs. 56 
(p=0.05) 
  60 vs. 44 
(p=0.05) 
     
Manoussakis 
et al, 2004 
23.9 vs. 
38.5  
(p=0.008) 
7.0 vs. 
38.5 
(p=<0.001
) 
28.6 vs. 64  
(p<0.001) 
100% both 
groups 
77.3 vs. 
69.2 
(p=0.436) 
 Anticardiolipin antibodies 
52.9 vs. 45.8 (p=0.639) 
Anti-U1 nRNP antibodies 
12.7 vs. 11.5 (p=0.999) 
Anti-Sm  
11.3 vs. 7.7 (p=0.999) 
Cryoglobulins  
14.7 vs. 15.8 (p=0.999) 
  26.3 vs. 7.7  
(p=0.03) 
Szanto et al, 
2006 
74 vs. 
94.64 
 (p<0.01) 
44 vs. 
73.21 
 (p<0.01) 
31.65U/m
L vs. 
120.39 
u/mL  
(p=0.126) 
 223.35 vs. 
132.51 
(p<0.01) 
 Anti-U1 nRNP  
41.6 vs. 37.1 (p=0.603) 
Anti-Sm  
38.7 vs. 22.9 (p=0.06) 
 
  36 vs. 25 
(p=0.218) 
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Pan et al, 
2008 
27.6 vs. 
71.4 
(p<0.001) 
17.4 vs. 
51.4 
(p<0.001) 
 74.4 vs. 
85.7 
(p=0.13) 
38.3 vs. 60  
(p=0.011) 
    42 vs. 40 
(p=0.816) 
Baer et al,  
2010 
26.8 vs. 
45.3 
(p<0.001) 
10 vs. 22.1 
(p<0.001) 
  59.1 vs. 
45.4 
(p<0.001) 
 
 Anticardiolipin 
49.1 vs. 41.7 (p=0.03) 
Anti-U1 nRNP  
28 vs. 13.3 (p<0.001) 
Anti-Sm  
17.3 vs. 9.7 (p=0.004) 
  21.9 vs. 17.8 
(p=0.14) 
RA vs. RA-sSS patients 
Antero et al, 
2011 
 
  58 vs. 70 
(p=0.24) 
30.6 vs. 30 
(p=0.95) 
 70.3 vs. 
75 
(p=1.0) 
 N/A   
Haga et al, 
2012 
  156.46 vs. 
54.90 
(p=NS) 
  136.89 
U/mL vs. 
125.17 
U/mL 
(p=NS) 
 ESR 
20.53 vs. 
14.90 (p=NS) 
CRP 
1.52 vs. 1.20 
(p=NS) 
  
He J et al, 
2013 
4.69 vs. 
39.2 
(p=0.001) 
1.39 vs. 
14.9 
(p=0.001) 
75.6 vs. 
95.7 
(p=0.001) 
51.7 vs. 
79.8 
(p=0.001) 
 71.9 vs. 
77.8 
(p=0.5) 
 N/A IgA 
33.6 vs. 48.5 
(p=0.106) 
IgG 
35.6 vs. 54.3 
(p=0.010) 
IgM 
10.6 vs. 11.8  
(p=0.951) 
0.5 vs. 9.5 
(p=0.001) 
Abdelghani 
et al, 2014 
1.5 vs. 0 
(p=1) 
 81.8 vs. 
67.1 
(p=0.5) 
53.8 vs. 
63.6 (p=0.1) 
 64 vs. 90 
(p=0.1) 
B2-m serum mean level  
1.9 mg/l vs. 2.4 
mg/l(p=0.02) 
ESR  
20.9 vs. 24.8 
(p=0.4) 
CRP 
14 vs. 12.6 
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Legend: ACA- anti-centromere antibodies; anti-CCP- anti-cyclic citrullinated peptide antibody; anti-dsDNA - anti-double stranded DNA; ANA- antinuclear antibody; anti-
Scl70 - anti-topoisomerase antibody; anti-Sm - anti-smith antibody; anti-U1-RNP - anti-nuclear ribonucleoprotein antibody; B2-m - beta 2 microglobulin; RF-Rheumatoid 
factor. 
 
 
(p=0.7) 
Brown et al., 
2015 
  76.8 vs. 
61.8 
(p=0.008) 
  73.8 vs. 
61.0 
(p=0.008) 
    
SSc vs. SSc-sSS patients 
Osial et al, 
1983 
5 vs. 29  0 vs. 41 14 vs. 50 32 vs. 65      
 
 
Avouac et al, 
2006 
0 vs. 26  
(p=0.003) 
24 vs. 53 
(p=0.05) 
74 vs. 90 
(p=NS) 
  Anti-Scl70 
33 vs. 5 (p=0.04) 
ACA 
12 vs. 63 (p=<0.0001) 
ESR 
18 vs. 14 
(p=NS) 
CRP 
7.5 vs. 4 
(p=NS) 
  
Salliot et al, 
2006 
      Anti-Scl 70 
21.9 vs. 15.4 (p=0.66) 
ACA 
40.4 vs. 61.5        (p=0.09) 
Cryoglobulins 
5.3 vs. 20 
(p=0.09) 
   
Kobak et al, 
2013 
10.3 vs. 
32.5 
(p=0.048) 
5.1 vs. 15 
(p=0.576) 
19.2 vs. 
72.5 
(p=0.001) 
28.2 vs. 90 
(p<0.01) 
  Anti-Scl70 
55.1 vs. 92.5 (p=0.032) 
ACA 
26.9 vs. 80  
(p=0.001) 
   
Myositis vs. myositis/sSS patients 
Vancsa et al, 
2010 
8.5 vs. 11 5.4 vs. 11  25.4 vs. 44 10 vs. 0  Anti-U1-RNP  
2.3 vs. 0 
Anti Jo-1 
18.5 vs. 0 
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Abstract 
 
Objective: The epidemiology of polyimmunitypolyautoimmunity in Sjögren's syndrome (secondary Sjögren's syndrome - sSS) is not well-
defined and was not investigated before using a systematic approach. We conducted a systematic review of the epidemiology of sSS associated 
with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), scleroderma and myositis, assessing the prevalence rates (PRs) and clinical 
and serological features of sSS.  
Methods: A systematic literature search of PubMed and Embase databases (updated to March 2016) was performed to identify all published 
data on prevalence rate, demographic profile, clinical manifestations, laboratory features and causes of death associated with sSS. The 
prevalence rates of pSS were summarised with PRs and 95% CIs.  
Results: The literature search identified 1639 citations, out of which 42 fulfilled the inclusion criteria. Only 19 studies had moderate to good 
quality and were selected for the meta-analysis. According to a random-effects model, the pooled PR for sSS associated with RA was 19.5% 
(95% CI 11.2 to 27.8) and the pooled PR for sSS associated with SLE was 13.96% (95% CI 8.88 to 19.04). The female/male ratio of sSS in the 
RA population was 14.7 (95% CI 7.09 to 256) and 16.82 (95% CI 1.22 to 32.4) in the SLE population.  
Conclusion: Prevalence rates of sSS vary widely in different populations. Both meta-analyses conducted in the RA and SLE populations were 
characterised by a high degree of study heterogeneity. The results of this meta-analysis highlighted the need for better quality population studies. 
 
Keywords: secondary Sjögren’s syndrome, polyimmunitypolyautoimmunity in Sjögren’s syndrome, prevalence, sex ratio, systematic review, 
meta-analysis.  
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Introduction 
Sjögren’s syndrome (SS) is a chronic systemic autoimmune disorder, which is associated in the majority of cases with lymphocytic infiltration of 
exocrine glands and epithelium, feature that is considered the histological hallmark of the disease (1). The T cell mediated attack on salivary and 
lacrimal glands results in chronic inflammation, which is considered in the majority of cases the leading cause toto glandular atrophy and 
deficient glandular function (2). Although, the temporal relationship between the presence of glandular inflammatory infiltrate and 
atrophic/fibrotic changes associated with ageing and/or disease progression is difficult to appreciate, the minor salivary gland biopsy have their 
role in the stratification and prognostication of patients with SS (3). 
SS is characterised clinically by symptoms of dry mouth (xerostomia) and dry eyes (xerophthalmia), known as sicca symptoms. SS can progress 
to affect many organ systems (lung, kidney, gastro-intestinal tract, skin, musculoskeletal, and peripheral and rarely central nervous system), and 
as a result, other clinical manifestations ranging from mild to more severe disease may occur, including: arthralgias, vasculitis, peripheral 
neuropathy, renal failure and interstitial lung disease (4). In addition, SS is associated with increased risk of lymphoma (5).  
SS can occur either alone as primary SS (pSS) or in association with another well-defined autoimmune condition, such as systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), or dermatomyositis (DM), in which case it is known as secondary SS 
(sSS) (6). Although, some researchers prefer to use the term of “polyauto-immunity” associated with SS rather than sSS (7, 8), for the purpose of 
our systematic review, we used the previously accepted terminology of sSS, which enabled us to identify all the relevant papers. In addition, the 
term “polyautoimmunity” refers to clusters of autoimmune conditions, which may include or not autoimmune rheumatic diseases (8).  Previous 
papers focused predominantly on prevalence studies and distinct immunologic differences between different sSS subtypes, rather than 
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differences in clinical presentations or controversies regarding the patients’ diagnosis.  
The diagnosis of SS cannot be made on a single test or symptom. The variability in presentation of SS has led to a difficulty over the years in 
establishing universally accepted classification criteria. Therefore, there has been a variation in prevalence estimates in the few epidemiological 
studies that have been documented, as they used different classification criteria (1, 9). Although the clinical features of pSS are relatively well-
researched in large epidemiological studies (10, 11), there are very few studies looking at the epidemiology and clinical and serological features 
of sSS.  The authors felt that a systematic review of the epidemiology of sSS was needed in order to establish any significant differences in the 
presentation of sSS according to the background rheumatic condition of patients that might have impact on their long-term management.  
 
Over the last few decades, diagnostic criteria have varied according to different national and international groups. At present, the most widely 
accepted and cited criteria are the American-European consensus group classification criteria (AECG), which were published in 2002 as a 
revision from the original European Study group criteria described in 1996 (2, 12). Interestingly, the presence of anti-Ro/La antibodies has not 
been included as a mandatory classification criteria for sSS, since it was not shown to be significant in previous analysis (13). New classification 
criteria for SS were recently developed and validated (14, 15). Although, they do not introduce any significant changes, they have been validated 
in three international patient cohorts, and emphasised the role of expert opinion in diagnosing SS.  
 
Methodology 
 
We performed a PUBMED and EMBASE search for articles involving humans only, published between 1984 and 2016. The MESH terms used 
were: secondary Sjögren’s, epidemiology of Sjögren's syndrome, secondary Sjögren’s and systemic lupus erythematosus, secondary Sjögren’s 
and rheumatoid arthritis, secondary Sjögren’s and systemic sclerosis/scleroderma/CREST syndrome, and secondary Sjögren’s and myositis. As 
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criteria for study selection, we considered all the studies on the epidemiology, diagnosis and follow-up of patients with sSS.  We excluded 
editorials, commentaries, animal studies, questionnaire studies, case reports, case-series, and studies of treatment (Figure 1). 
We extracted data on prevalence, demographic profile, clinical manifestations, laboratory features, underlying autoimmune diseases and causes 
of death from the selected articles, where available, and organised them in tables.  
 
Studies were grouped according to the following patient categories: 1). secondary Sjögren’s and systemic lupus erythematosus, 2). secondary 
Sjögren’s and rheumatoid arthritis, 3). secondary Sjögren’s and scleroderma and 4). secondary Sjögren’s and myositis. We present our results 
data under the following headings: prevalence and demographics of secondary Sjögren’s syndrome in different autoimmune diseases, clinical 
and laboratory features of Sjögren’s syndrome in different autoimmune diseases, and morbidity and mortality associated with secondary 
Sjögren’s syndrome. Prevalence rates were calculated using 95% CI.  Pooled prevalence rates and sex ratios were calculated using a random 
effects model (based on the Q and I
2
 tests of heterogeneity among studies). 
 
Results: 
 
The initial research yielded 1639 articles, which were screened for titles and abstracts, of which 37 were selected for review based on the 
inclusion and exclusion criteria mentioned above (the detailed process of paper selection is detailed in Figure 1). Following an additional manual 
search of other relevant articles, we identified 42 full papers and abstracts, which met the inclusion criteria and were analysed further.  
We appreciate a risk of reporting bias for the majority of studies as they addressed different populations and used different classification criteria 
for sSS. The study quality was weighted as poor, moderate and good based on the following criteria: number of patients, the use of established  
SS classification criteria, data about patient sex, ethnicity and disease duration, inclusion of lip biopsy in the classification criteria (especially as 
the serology is likely to be positive in lupus patients, irrespective of concomitant SS). The assessment of study quality was reviewed 
independently by HA and CC. There was an 82% consensus. The studies in which case the consensus was not reached, were further evaluated by 
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the third author (EJ) and graded based on the assessment made by two of the three authors. The details of study quality assessment were included 
in Table 1. Based on this selection, 9 SLE studies and 11 RA studies assessed as having moderate to good quality were included in the final 
meta-analysis.  
 
Prevalence and demographics of SS associated with different autoimmune diseases 
 
Our search identified 40 worldwide studies, which evaluated the prevalence of sSS in patients with RA, SLE, SSc and myositis. The study 
designs included were retrospective, cross-sectional and prospective (Table 2). The number of patients used in each study ranged from 6 to 2694. 
 
Criteria 
Different criteria were used across the different studies to classify patients as having sSS, including AECG (14), ECC (7), Japanese classification 
criteria (1), and other criteria (9). Nine studies did not specify the classification criteria they used.  
 
Prevalence 
We found 18 studies which looked at the prevalence of RA-sSS (between 1987-2013) (16-33), 13 for SLE-sSS (1998-2015) (34-46), 6 for SSc-
sSS (1983-2013) (47-52) and 3 for myositis-sSS (2011-2014) (53-55). The prevalence ranged from 3.6%-55% for RA-sSS, 5%-22% SLE-sSS, 
14%-60% SSc-sSS and 10-23% for myositis-sSS. In the RA-sSS studies three of the highest reported prevalence all came from studies carried 
out in Greece on Greek patients (31- 39.8%)(18, 20, 23).  
 
Gender 
Not all studies reported the gender of the patients, however in the 15 that did, females were predominantly affected (82%-100%). Less than half 
of all studies (17/37) highlighted the ethnicity of the patients included in the study. 
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Age 
In five studies (36, 39, 42, 44, 45) SLE-sSS patients were reported to be significantly older when compared to those with SLE only (48.3 vs. 
36.1, p<0.001; 41.3 vs. 35.8, p=0.003; 50.8 vs. 43.6, p=0.01; 41 vs. 35 p=0.03, and 49.5 vs. 41.4 p<0.001). This was not found to be the case for 
RA-sSS patients when compared to RA patients as reported by two studies (63.0 vs. 59.2, p=0.33 and 66.36 vs. 62.40, p=NS) (21, 28). There 
was also no significant difference in age between SSc vs. SSc-sSS patients reported in three studies (56 vs. 54, p=NS; 50.2 vs. 55, p=0.18, and 
48.3 vs. 50.5 p=NS) (50-52).   
 
Disease duration 
Disease duration was reported in 26/40 studies and varied across all studies ranging from 4 months -12 years for RA-sSS (16, 20-23, 25, 27-29, 
32, 33), 3-46 years SLE-sSS (34-37, 39, 41, 42, 44), 7-8 years SSc-sSS (47, 50-52), and 67 months to 20 years for myositis-sSS (53-55). 
 
Only the RA-sSS studies looked into the relationship between disease duration and sSS incidence rate. There were conflicting reports with 
regard to whether RA disease duration plays any role in the reported occurrence rate of sSS. Two studies found that the cumulative prevalence of 
sSS did increase with RA duration (19, 29). This finding however, was not supported by four other studies (21, 22, 25, 28). 
 
 
Clinical and laboratory features of sSS associated with different autoimmune diseases: 
 
We identified 17 studies assessing the clinical and laboratory features of sSS (Tables 3-4). The reported clinical features varied depending on 
which condition associated with sSS was being looked at.  
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SLE-sSS 
Of the seven studies (36, 37, 39, 42, 44-46) assessing clinical features of SLE-sSS, the majority reported data on the presence of renal 
involvement and central nervous system (CNS) involvement. Renal involvement was found to be significantly reduced in SLE-sSS patients 
across five studies (36, 37, 39, 44, 45), while thyroiditis was found to be significantly higher. CNS involvement prevalence, although reduced in 
SLE-sSS patients, was not significant in any of the three studies. Only one study reported no cases of  lymphoma in their cohort of 26 SLE-sSS 
patients (36), although they reported 8 cases of lymphoma in their pSS comparative group (N=86) . 
Regarding serological markers, only anti-Ro/SSA and anti-La/SSB antibodies were significantly raised in SLE-sSS compared to SLE patients in 
five studies (36, 37, 39, 42, 44). Anti-dsDNA was higher in SLE patients and this reached significance in four studies (37, 39, 42, 44). 
Thrombocytopenia was lower in SLE-sSS patients, although this was only significant in two studies (36, 45).    
 
Koskenmies et al. reported that sSS was most commonly observed in patients with subacute cutaneous lupus erythematosus (SCLE) and SLE 
than in patients with discoid lupus erythematosus (16.4% vs. 22.1% vs. 2.3%, p<0.001) (43) . 
 
RA-sSS 
Five studies addressed clinical features of RA-sSS patients (21, 22, 25, 27, 28). The majority reported data on joint swelling, tender joints and 
disease activity score assessing 28 joints (DAS 28 score). Half the studies reported that tender joints were significantly higher in RA-sSS patients 
compared to RA patients (22, 27), while the other half reported no significant difference (21, 28). Only one reported study looked at other 
clinical features including lymphadenopathy, thyroiditis, lung, renal and CNS involvement (27). 
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Laboratory analysis was mainly focused on RF, anti-CCP, CRP and ESR levels. There was inconsistency concerning the reported RF levels. 
Three studies (22, 25, 27) reported higher levels of RF in RA-sSS patients, one being significant, while the opposite was found in two other 
studies, although not significant (21, 28). 
 
SSc-sSS 
Four studies (47, 50-52) reported data about lung involvement, mainly pulmonary fibrosis (PF) and pulmonary arterial hypertension (PAH).  PF 
occurred significantly less frequently in SSc-sSS patients. Only one study reported lower occurrence of PAH in SSc-sSS, which was significant 
(52). 
 
The majority of studies looked at anti-topoisomerase 1 antibodies and anti-centromere (ACA) levels. ACA levels were significantly higher in 
SSc-sSS patients across all three studies (50-52). However, there was discrepancy regarding the prevalence of anti-topoisomerase 1 antibodies.  
 
Myositis-sSS 
 
In one study, all six patients with both diseases presented with a pattern of muscle weakness typical of IBM (53). Five IBM-sSS patients were 
treated with prednisolone and methotrexate, four of whom had temporary symptomatic improvement (6-24 months). This was a far greater 
response in comparison to the IBM only group in whom only 27% had a transient response to treatment. 
 
 
Immunogenetics 
 
SLE-sSS 
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Immunogenetic analysis was carried out in two studies. In one study there was no significant difference between the SLE and SLE-sSS patients 
when looking at the HLA alleles (42). However, in another study, the HLA associations distinguished the SLE group from those with SLE-sSS. 
Those with SLE  were found to have increased phenotype and allele frequencies for DRB1*1501 (p=0.020 and p=0.015, respectively) and 
DQB1*0602 (both p<0.001) that was significant (36). 
 
Myositis-sSS 
In the study mentioned above (53), all six patients carried the HLA-DRB1*0301 allele or its equivalent HLA-DR3 serological specificity. They 
also carried either all or some of the major markers of the 8.1 MHC ancestral haplotype. This allele was also reported to be highly prevalent 
among the Norwegian patients included in another study (25%), which found a prevalence of rheumatic disorders of 24%, which is twice as high 
as previously reported (55). 
 
Morbidity and mortality associated with sSS 
 
In a few RA studies other aspects of the disease including its effect on quality of life and its involvement in haematological malignancies was 
studied.   
 
Health status 
 
RA-sSS 
In three of the five studies measuring health status there was no difference in the DAS-28 mean scores in RA-sSS compared to RA patients (21, 
25, 28). In two other studies (22, 27) however, a higher DAS-28 score was found in RA-sSS patients, compared to RA patients (6.44 vs. 5.96, 
p=0.02 and 5.08 vs. 4.20, p=<0.001, respectively).   
Page 44 of 71
Scandinavian Journal of Rheumatology
Scandinavian Journal of Rheumatology
For Peer Review
 
One study (22) looked at other health status measures including pain visual analogue scale (VAS) scale, fatigue VAS and Modified Health 
Assessment Questionnaire (M-HAQ), and found that the RA-sSS patients scored significantly higher in all three tests in comparison to RA 
patients (43.1 vs. 32.9, p =<0.01; 49.8 vs. 39.7, p=0.03, and 1.75 vs. 1.55, p=0.04, respectively). Another study (28) looked at both M-HAQ and 
pain VAS tests and reported similar findings in both groups of patients (0.84 vs. 0.81, p=0.7, and 35.9 vs. 42.4, p=0.3, respectively). 
 
 
 
Haematological malignancy and mortality 
 
SLE-sSS 
Nossent et al. (45)  reported a significantly reduced overall mortality in patients with SLE-sSS compared to SLE patients (4% vs. 13.5%, 
p=0.01). In two studies in which patients where followed up for three years and 8 years respectively, none of the patients developed lymphoma 
(36, 45). 
 
Martens et al. looked at the survival of sSS patients in a population-based sample in Minnesota, USA between 1976 and 1992. Of the 74 cases 
24 (33%) had sSS and 50 (67) had pSS. It found that when compared with the general population, SS patients had increased mortality (p=0.04). 
Furthermore, when studied separately, the mortality was increased in sSS compared to pSS patients (p=<0.005), with the majority of sSS 
patients having associated RA (p= 0.86) (56). 
 
RA-sSS 
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With regard to haematological malignancies, studies have reported increased incidence of non-Hodgkin’s lymphoma (NHL) in RA-sSS patients. 
A Finnish study carried out by Kauppi et al. compared the incidence of NHL in 9,469 RA patients and 709 sSS patients.  This study found the 
incidence of NHL to be almost two-fold in patients with RA-sSS (8.7, CI=4.3-1.6) compared to RA patients (4.5, CI=1.5-11) (56).  
 
SSc-sSS 
Baldini et al. described a new clinical phenotype of “ACA-positive limited scleroderma/SS overlap syndrome”, which in their retrospective 
study was characterised by a benign SSc clinical course but at a high risk of non-Hodgkin's lymphoma (57). 
 
 
 
Meta- analysis of prevalence rates and sex ratios of sSS associated with SLE and RA 
 
The results of the meta-analysis revealed a pooled prevalence of 13.96% (95% CI 8.88 to 19.04) in the SLE population and 19.5% (95% CI 11.2 
to 27.8) in the RA population. The statistical analysis of the selected studies revealed a high degree of heterogeneity as expected (I2 = 99.98 for 
the SLE studies and 99.92 for the RA studies; therefore, we used a random effect statistical model for calculating the pooled prevalence). The 
results of the meta-analysis are presented in Figures 2 and 3.   
 
We also analysed the sex ratio of sSS patients in the SLE and RA populations, which revealed a clear predominance of female patients (four RA 
studies reported that all their sSS/RA patients were females). The female: male ratios were 16.82 (95% CI 1.22 to 32.4) for the SLE-sSS patients 
and 14.7 (95% CI 7.09 to 256) for the RA-sSS population.  
 
Discussions 
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Secondary SS is characterised by a heterogeneity of clinical manifestations, serological markers and symptoms, which are influenced by 
patients’ underlying pathology. Unfortunately, large prospective studies comparing patients with sSS associated with different autoimmune 
rheumatic diseases are lacking. Previous studies were interested in comparing the clinical and laboratory features of an autoimmune disease 
alone or associated with sSS (as the majority of the studies included in this systematic review), or aimed to compare the epidemiology of pSS vs. 
sSS (this was beyond the scope of our systematic analysis). Other papers explored the communality of serological abnormalities and shared 
clinical picture in distinct autoimmune rheumatic diseases, such as RA and pSS (58), or advocated that the association of SS with multiple 
autoimmune diseases, is better described as “polyimmunitypolyautoimmunity” (7), as discussed in introduction. However, this terminology is 
not particularly exact in relation to the presence of clinical and serological features of SS in the context of rheumatic conditions (which is the 
focus of this review), as it also refers to associations of SS with other autoimmune diseases (8) .    
 
There is evidence of a great degree of heterogeneity within all these populations; although previous research established that pSS is associated 
with a different disease phenotype compared to sSS: e.g. pSS patients had a higher frequency of parotid gland enlargement and Ro and La 
antibody positivity (59), or had significantly higher levels of IL-2 and IL-6 in their saliva (60). An old study also suggested that extraglandular 
features are more common in pSS compared to sSS (61).   
 
Our study could not address any controversies regarding the accuracy of patients’ diagnosis (e.g. many clinicians’ might decide based on their 
expert opinion to diagnose a patient as having RA associated with SS rather than symmetrical polyarthritis in the context of primary SS). In 
addition, our systematic review does not imply that patients with sSS associated with different ARDs have similar features (e.g. SLE and SS 
patients might have similar clinical presentation, which is not the case with patients with SS associated with SD or myositis). Even if only 
moderate-good quality studies were included in the meta-analysis, the studies with poor quality were also detailed in the paper. In addition, our 
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systematic review also reported on papers relevant for the article theme, even if not selected by our systematic approach, such as papers referring 
to patients defined as having overlapping syndromes rather than sSS (57) or which contained no data about sSS prevalence (62). 
 
Our analysis revealed that sSS is more common in women, irrespective of the underlying autoimmune disease. The confidence intervals of sex 
ratios in the SLE and RA patients with associated sSS reflected again the high heterogeneity of the studies and the inclusion of studies, which 
reported the presence of sSS exclusively in the female population.  
 
Despite the effort to define the sSS patient population better, clinicians are still unable to answer practical questions regarding the difference in 
the long term outcome of sSS associated with an autoimmune disease compared to having only an autoimmune disease, or regarding the best 
way to stratify these patients to enable the choice of the most suitable therapeutic options. It is recognized that sSS is characterised by significant 
amount of variability in clinical presentation, which is influenced by the concomitant autoimmune disease; however, different studies reported 
various epidemiological features in the context of similar background autoimmune disease. This variation can be in part explained by the SS 
classification criteria applied, as well as patient selection criteria, their ethnicity or genetic background, and possible reporting bias (45, 63). Our 
results show that Raynaud’s phenomenon, thyroiditis and Ro, La antibody positivity seemed to be more frequent in SLE-sSS patients compared 
to SLE group, while renal involvement and presence of dsDNA, and anti Sm antibodies were more common in the latter group. A less clearly 
defined trend was identified in the case of thrombocytopaenia and lung involvement, while the CNS involvement was reported in only one study 
as more frequent in the SLE-sSS group.  
 
The number of tender and swollen joints was more commonly reported in the RA compared to RA-sSS group, however, the RA-sSS group had 
more CNS involvement, Raynaud’s phenomenon, thrombocytopaenia and hypergammaglobulinaemia.  
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In the scleroderma and myositis groups, the main differences were seen in the positivity of antibodies (the disease characteristic ones being more 
prevalent in their corresponding group). However, as there was no significant overlap between the clinical features of these autoimmune 
conditions, and the quality of the studies was poor, no assumptions can be made about the difference in the clinical presentation of SSc-sSS 
made for patients’ clinical phenotype, apart from additional symptoms of dryness, and a possible subset of patients with overlap syndrome with 
milder disease presentation (57).  
Importantly, studies of both SLE and SSc populations hinted at the possibility that these patients have the highest risk of lymphoma of all the 
autoimmune disease groups (44, 57).  
 
Our systematic review included mainly prevalence studies (as the large population studies were lacking) and reported prevalence rather than 
incidence figures (as sSS is reported in patient groups rather than general population, and the appreciation of the newly diagnosed cases per year 
necessitates long prospective studies not available in the literature). The quality of the studies included in the analysis was poor to moderate 
because of the following reasons: significant heterogeneity of patient inclusion criteria (12 studies did not use validated classification criteria and 
were excluded from the final analysis); variable number of patients included (from 6 to 2694); different proportion of patients classified as 
having SS based on salivary gland biopsy (14 studies included the biopsy as a classification criteria for all the sSS patients, and 5 studies for a 
variable proportion of patients); limited geographic areas (only one study evaluated patients from two different countries), and difficulty to 
extrapolate data to other populations (there were no studies from South America, Africa or Oceania).  There was also evidence of significant 
statistical heterogeneity in our meta-analysis of sSS prevalence in SLE and RA patients, probably due to both, clinical and methodological 
differences between studies.  
 
The authors identified an unmet need for a consensus regarding the diagnostic/classification criteria for sSS in the context of different underlying 
autoimmune diseases, especially in the group of SLE/sSS, which is characterised by shared clinical and serological features that make the 
diagnosis difficult in the absence of a positive salivary gland biopsy.   
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In conclusion, this is the first systematic review and meta-analysis of the epidemiology of sSS, which aimed to evaluate the characteristics of this 
heterogeneous population. Because of the lack of prospective longitudinal data in large population studies, there are still unanswered questions 
related to the malignancy risk of these patients or their clinical and laboratory features in less common autoimmune diseases. 
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Figure legends: 
Figure 1: Flowchart of study selection. 
Figure 2: Meta-analysis of the prevalence of sSS in SLE patients. 
Figure 3: Meta-analysis of the prevalence of sSS in RA patients. 
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Table 1: Studies reporting the disease duration and relationship with the sSS prevalence in RA patients. 
 
 
Study Disease duration  Relation between 
prevalence of sSS and RA 
disease duration 
Uhlig et al.,1999 12.2 years None 
Antero et al., 2011 10.2 +/- 7 years None 
Abdelghani, 2014 15.6 years None 
Haga et al.,2012 10.63 years None 
Carmona et al.,2003 - Prevalence at 10 years 17%, 
and 25% after 30 years  
Young et al.,2000 10 years Prevalence at 1 year 4%, and 
12% after 10 years 
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Table 2: Studies included in the systematic review 
 
 Study 
design 
Country 
 
Number 
of  
patients  
Criteria 
used 
Number 
of sSS 
cases (%) 
Ethnicity Female/male 
(n) 
 
Disease duration 
(years/months) 
Salivary gland 
biopsy  
Study quality 
Systemic lupus erythematosus 
Nossent et al, 
1998 
P Norway/ 
Netherlands 
 
138 ECC N=27 
(19.6%) 
NA 22/5 8 years 12 patients 
tested 
Moderate 
McDonagh et al, 
2000 
R UK 
(London) 
215 ECC N=28 
(13%) 
NA NA 18 years All tested  Moderate 
Gilboe et al, 
2001  
R Norway 
(Oslo) 
81 ECC N=9 
(11%) 
Caucasian 9/0 8 years NA Moderate 
Bowman et al, 
2003   
 
CS 
UK 
(Birmingham) 
96 AECG N=18 
(19%) 
Caucasian 18/0 10.9 years NA Moderate 
Manoussakis et 
al, 2004 
R Greece 
(Athens) 
283 AECG N=26 
(9%) 
Caucasian  26/0 3.5 years  All tested Good 
Szanto et al, 
2006 
R Hungary 
(Debrecen) 
362 AECG N=56 
(15%) 
Caucasian 52/4 8.1 years All tested Good 
Scofield et al, 
2007 
R USA 
(Oklahoma) 
1138 NA N=169 
(15%) 
NA NA NA NA Poor 
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Pan et al, 2008 R China 542 AECG N=35 
(6%) 
Asian Chinese 32/3 3.7 years All tested Good 
Koskenmies et 
al, 2008 
R Finland 
(Helsinki) 
77 NA N=17 
(22%) 
NA NA NA NA Poor 
Baer et al, 
2010 
CS USA 
(Marylands) 
1790 AECG N=259 
(14.5%) 
White= 70.7 
African 
American= 25.5 
Hispanic= 1.9 
Asian= 1.2 
253/6 19.5 years All tested Good 
Maria et al, 2013  CS/R Spain 
(Lugo) 
150 NA N=27 
(18%) 
NA 27/0 NA NA Poor  
Lockshin et al, 
2015 
R USA 600 Other N=28 
(5%) 
NA NA NA NA Poor 
Aggarwal et al, 
2015 
 
L USA 2694 AECG N=548 
(20%) 
Mixed (White, 
Black, 
Hispanic, 
Asian and 
native) 
504/44 20 years NA Good 
Rheumatoid arthritis 
Andonopoulos et 
al, 1987 
P Greece 111 Other N=34 
(31%) 
Greek NA 3.3 - 9.1 years All tested Good 
Martinez Castro 
et al, 1990  
CS Spain 45 NA N=24 
(55%) 
Spanish NA NA All tested Poor 
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Drosos et al, 
1992 
CS Greece/British 
Ioannina/London 
G=108 
B= 107 
Other GK N=43 
(39.8%) 
BS N=17 
(15.9%) 
Greek/British NA NA All tested Moderate 
Uhlig et al, 1999 CS Norway 
(Oslo) 
636 ECCN N=46 
(7%) 
NA NA 12.2 years NA Moderate 
Cimmino et al, 
2000 
CS Italy 
(Northern) 
587 Other N=103 
(17.5%) 
Italian NA 10 years NA Poor 
Mattey et al, 
2000 
CS Spain 
(Lugo) 
179 Other N=22 
(12.3%) 
NA NA NA NA Poor 
Young et al, 
2000  
P UK 732 NA N=54 
(7%) 
NA 46/9 
 
4 - 11 months NA Poor 
Ioannidis et al, 
2002 
CS Greece 
(Ioannina/ 
Athens) 
174 ECC N=57 
(32.7%) 
Greek NA 10.5 years NA Moderate 
Turesson et al, 
2003 
R USA 
(Minnesota) 
609 Other N=58 
(9.5%) 
NA NA 46 years NA Poor 
Carmona et al, 
2003 
CS Spain  788 ECC N=134 
(17%) 
Spanish NA NA NA Moderate 
Fujita et al, 2005  P Japan 
(Tokyo) 
72 Japanese  N=7 
(10%) 
Japanese 7/0 
 
NA NA Poor 
Calgüneri et al, 
2006 
R Turkey 
(Ankara) 
526 NA N=28 
(5.3%) 
NA NA NA NA Poor 
Antero et al, 
2011 
CS Brazil 
(Curitiba) 
82 AECG N=20 
(24.3%) 
NA 18/2 10.2 years All tested Good 
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Kosrirukvongs et 
al, 2012 
CS Thailand 
(Siriraj) 
61 Other N=14 
(22.2%) 
NA NA NA NA Poor 
Haga et al, 2012 CS Denmark 
(Esbjerg) 
307 AECG N=11 
(3.6%) 
NA NA 10.6 years NA Moderate 
Aliko et al, 2010 CS Albania 
(Tirana) 
88 ECC N=13 
(14.8%) 
Albanian NA 9.5 years NA Moderate 
He J et al, 2013 R China 
(Beijing) 
509 AECG N=74 
(14.5%) 
Chinese 64/10 15.10 months 16 patients 
tested 
Good 
Abdelghani, 
2014 
CS France 
(Strasbourg) 
76 AECG N=11 
(14%) 
French NA 15.6 years 9 patients tested Moderate 
Brown et al., 
2015 
CS USA 
(Boston) 
829 AECG N=85 
(10.3%) 
White= 89.4 76/9 16.9 years NA Good 
Systemic sclerosis 
Osial et al, 1983 CS USA 
(Pennsylvania) 
58 
 
Other N=17 
(29%) 
NA 16/1 7.3 years All tested  Good 
Andonopoulos et 
al, 1988 
P Greece 44 
 
Other N=9 
(20.5%) 
 
NA NA NA All tested  Poor 
Drosos et al, 
1991 
CS Greece 23 
 
NA N=14 
(60%) 
 
NA NA NA All tested  Poor 
Avouac et al, 
2006 
P France 
(Paris) 
133 
 
AECG N=19 
(14%) 
NA 16/3 7 years 91 patients 
tested 
Good 
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Legend: CS – cross-sectional study; NA – information not available; P – prospective study; R – retrospective study.  
 
 
 
  
Salliot et al, 2006 R France 
(Paris) 
121 
 
AECG N=27 
(22%) 
 
NA 24/3 7.3 years All tested Good 
Kobak et al, 2013 CS Turkey 
(Izmir) 
118 
 
AECG N=40 
(33.9%) 
 
 
NA 38/2 8.2 years 74 patients 
tested 
Good 
Baldini et al., 
2013 
R Italy (Pisa) 209-
systemic 
sclerosis 
402 
pSS 
Le Roy 
 
AECG 
N=41 NA NA NA NA Moderate 
Myositis 
Rojana-
Udomsart et al, 
2011 
CS Australia 6 AECG N=6 
(12%) 
NA 5/1 
 
20 years NA Poor 
Vancsa et al, 
2010 
CS/R Hungary 169 NA N=9 
(23%) 
NA NA 6 years  NA Poor 
Dobloug et al, 
2014 
CS Norway 100 NA N=10 
(10%) 
NA NA 5.5 years NA Poor  
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Table 3 : Clinical features of patients with sSS 
Disease/Ref Arthritis 
(% 
patients) 
Swollen 
joints 
(% 
patients) 
Tender 
joints 
(% 
patients) 
DAS 28 
score 
Raynaud’
s 
(% 
patients) 
Photo 
sensitivity 
(% 
patients) 
Lymph 
adenopathy 
(% patients) 
Thyroiditis 
(% 
patients) 
Lung 
involvement 
(% 
patients) 
Renal 
involvement 
(% 
patients) 
Nervous 
system 
involvement 
(% patients) 
Lymphoma 
(% patients) 
SLE vs. SLE-sSS patients 
Nossent et al, 
1998 
88 vs. 92 
(p=NS) 
        38 vs. 19 
(p=0.04) 
NPSLE 
18 vs. 19 
(p=NS) 
0% 
Gilboe et al, 
2001 
         19 vs. 0  
(p<0.05) 
  
Manoussakis et 
al, 2004 
51.3 vs. 
76.9 
(p=0.27) 
   43.4 vs. 
80.8  
(p <0.001) 
 
 46.1 vs. 19.2 
 (p=0.004) 
 11.8 vs. 11.5 
(p=0.891) 
55.3 vs. 11.5  
(p=0.005) 
19.7 vs. 11.5 
(p=0.55) 
0% 
Szanto et al, 
2006 
    28 vs. 35.7 
(p=0.396) 
  6 vs. 21.4 
 (p=0.023) 
24 vs. 28.5 
(p=0.59) 
66 vs. 57.1 
(p=0.312) 
36 vs. 25 
(p=0.21) 
 
Scofield et al, 
2007 
       12.7 vs. 29.6 
(p<0.000) 
    
Pan et al, 2008   60.9 vs. 
77.1 
(p=0.056) 
  14.2 vs. 
8.6 
(p=0.45) 
   66.7 vs. 48.6 
(p=0.03) 
9.5 vs. 2.9 
(p=0.35) 
 
Baer et al, 
2010 
73.2 vs. 
81.3 
(p=0.006) 
   49.5 vs. 66 
(p<0.001) 
52.9 vs. 
68.3  
(p=0.001) 
   Proteinuria 
43.1 vs. 29.0 
(p<0.001) 
Haematuria 
30.9 vs. 22.8 
(p=0.008) 
Nephrotic 
syndrome 
20 vs. 8.9 
(p<0.001) 
Psychosis 
3 vs. 6.6 
(p=0.005) 
Seizures 
9.3 vs. 11.6 
(p=0.25) 
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RA vs. RA-sSS patients 
Uhlig et al, 
1999 
100 7.0 vs. 
8.5 
(p=0.17) 
6.1 vs. 9.6 
(p=<0.01) 
4.20 vs. 
5.08 
(p<0.001) 
        
Antero et al, 
2011 
100   3.35 vs. 
2.81 
(p=0.1) 
        
Haga et al, 
2012 
100 0.28 vs. 
0.73  
(p=NS) 
1.1 vs. 2.2 
(p=NS) 
3.1 vs. 2.7   
(p=NS) 
        
He J et al, 2013 100 12.9 vs. 
15.8   
(p<0.05) 
12.1 vs. 
14.5 
(p=0.019) 
5.9 vs. 6.4   
(p=0.009) 
  7.59 vs. 10.8  
(p=0.346) 
27.1 vs. 21.6 
(p=0.320) 
11.7 vs. 44.6  
(p<0.001) 
4.81 vs. 14.9 
(p=0.002) 
0.23 vs. 2.7 
(p=0.010) 
 
Abdelghani et 
al, 2014 
100 3.7 vs. 
3.2 
(p= 0.4) 
6.2 vs. 5.6  
(p=0.4) 
4.13 vs. 
4.05  
(p=0.8) 
1.5 vs. 
27.2 
(p=0.01) 
       
Brown et al., 
2015 
100   4.3 vs. 3.2 
(p=0.01) 
        
SSc vs. SSc-sSS patients 
Osial et al, 1983         Unspecified 
pulmonary 
disease  
64 vs. 65  
9 vs. 12    
Avouac et al, 
2006 
        Lung 
fibrosis  
45 vs. 11 
(p=0.02) 
PAH  
19 vs. 11 
(NS) 
   
Salliot et al, 
2006 
    94.7 vs. 
92.6  
(p= 0.98) 
   Lung 
fibrosis  
29 vs. 11.1 
(p=0.05) 
PAH 15.1 
vs. 7.4 
(p=0.60) 
14.9 vs. 3.7 
(p=0.21) 
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Legend: PAH - pulmonary arterial hypertension; NS - not significant; NPSLE- neuropsychiatric lupus. 
 
  
Kobak et al, 
2013 
        Lung 
fibrosis  
58.9 vs. 30 
(p=0.001) 
PAH 52.6 
vs. 30 
(p=0.001) 
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Table 4: Serological features of patients with sSS 
 
Disease/Ref Ro/ SSA 
antibodies 
(% 
patients) 
La/ SSB 
antibodies 
(% 
patients) 
RF 
(% 
patients/ 
U/mL) 
ANA 
(% 
patients) 
dsDNA 
(% 
patients) 
Anti 
CCP 
(% 
patients) 
Other antibodies/ 
markers 
(% patients) 
ESR/CRP 
(mm/h;  
mg/l) 
Hyper 
gamma 
globulinaemia 
(% patients) 
Thrombo 
Cytopaenia 
(% patients) 
SLE vs. SLE-sSS patients 
Nossent et 
al, 1998 
44 vs. 48 
(p=NS) 
38 vs. 33 
(p=NS) 
 88 vs. 87 
(p=NS) 
71 vs. 53 
(p=NS) 
 Anticardiolipin 
33  vs. 41 (p=NS) 
Anti-Sm 
21 vs. 15 (p=NS) 
Anti-U1 nRNP  
26 vs. 25 (p=NS) 
  9 vs. 26 
(p<0.05) 
Uhlig et al, 
1999 
 
  48.2 U/mL 
vs. 62.2 
U/mL 
(p=0.08) 
    ESR 
18.6 vs.  26.8 
(p<0.01) 
CRP 
11.9 vs. 13.8 
(p=0.33) 
  
Gilboe et al, 
2001 
36 vs. 89 
(p=0.05) 
11 vs. 56 
(p=0.05) 
  60 vs. 44 
(p=0.05) 
     
Manoussakis 
et al, 2004 
23.9 vs. 
38.5  
(p=0.008) 
7.0 vs. 
38.5 
(p=<0.001
) 
28.6 vs. 64  
(p<0.001) 
100% both 
groups 
77.3 vs. 
69.2 
(p=0.436) 
 Anticardiolipin antibodies 
52.9 vs. 45.8 (p=0.639) 
Anti-U1 nRNP antibodies 
12.7 vs. 11.5 (p=0.999) 
Anti-Sm  
11.3 vs. 7.7 (p=0.999) 
Cryoglobulins  
14.7 vs. 15.8 (p=0.999) 
  26.3 vs. 7.7  
(p=0.03) 
Szanto et al, 
2006 
74 vs. 
94.64 
 (p<0.01) 
44 vs. 
73.21 
 (p<0.01) 
31.65U/m
L vs. 
120.39 
u/mL  
(p=0.126) 
 223.35 vs. 
132.51 
(p<0.01) 
 Anti-U1 nRNP  
41.6 vs. 37.1 (p=0.603) 
Anti-Sm  
38.7 vs. 22.9 (p=0.06) 
 
  36 vs. 25 
(p=0.218) 
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Pan et al, 
2008 
27.6 vs. 
71.4 
(p<0.001) 
17.4 vs. 
51.4 
(p<0.001) 
 74.4 vs. 
85.7 
(p=0.13) 
38.3 vs. 60  
(p=0.011) 
    42 vs. 40 
(p=0.816) 
Baer et al,  
2010 
26.8 vs. 
45.3 
(p<0.001) 
10 vs. 22.1 
(p<0.001) 
  59.1 vs. 
45.4 
(p<0.001) 
 
 Anticardiolipin 
49.1 vs. 41.7 (p=0.03) 
Anti-U1 nRNP  
28 vs. 13.3 (p<0.001) 
Anti-Sm  
17.3 vs. 9.7 (p=0.004) 
  21.9 vs. 17.8 
(p=0.14) 
RA vs. RA-sSS patients 
Antero et al, 
2011 
 
  58 vs. 70 
(p=0.24) 
30.6 vs. 30 
(p=0.95) 
 70.3 vs. 
75 
(p=1.0) 
 N/A   
Haga et al, 
2012 
  156.46 vs. 
54.90 
(p=NS) 
  136.89 
U/mL vs. 
125.17 
U/mL 
(p=NS) 
 ESR 
20.53 vs. 
14.90 (p=NS) 
CRP 
1.52 vs. 1.20 
(p=NS) 
  
He J et al, 
2013 
4.69 vs. 
39.2 
(p=0.001) 
1.39 vs. 
14.9 
(p=0.001) 
75.6 vs. 
95.7 
(p=0.001) 
51.7 vs. 
79.8 
(p=0.001) 
 71.9 vs. 
77.8 
(p=0.5) 
 N/A IgA 
33.6 vs. 48.5 
(p=0.106) 
IgG 
35.6 vs. 54.3 
(p=0.010) 
IgM 
10.6 vs. 11.8  
(p=0.951) 
0.5 vs. 9.5 
(p=0.001) 
Abdelghani 
et al, 2014 
1.5 vs. 0 
(p=1) 
 81.8 vs. 
67.1 
(p=0.5) 
53.8 vs. 
63.6 (p=0.1) 
 64 vs. 90 
(p=0.1) 
B2-m serum mean level  
1.9 mg/l vs. 2.4 
mg/l(p=0.02) 
ESR  
20.9 vs. 24.8 
(p=0.4) 
CRP 
14 vs. 12.6 
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Legend: ACA- anti-centromere antibodies; anti-CCP- anti-cyclic citrullinated peptide antibody; anti-dsDNA - anti-double stranded DNA; ANA- antinuclear antibody; anti-
Scl70 - anti-topoisomerase antibody; anti-Sm - anti-smith antibody; anti-U1-RNP - anti-nuclear ribonucleoprotein antibody; B2-m - beta 2 microglobulin; RF-Rheumatoid 
factor. 
 
 
(p=0.7) 
Brown et al., 
2015 
  76.8 vs. 
61.8 
(p=0.008) 
  73.8 vs. 
61.0 
(p=0.008) 
    
SSc vs. SSc-sSS patients 
Osial et al, 
1983 
5 vs. 29  0 vs. 41 14 vs. 50 32 vs. 65      
 
 
Avouac et al, 
2006 
0 vs. 26  
(p=0.003) 
24 vs. 53 
(p=0.05) 
74 vs. 90 
(p=NS) 
  Anti-Scl70 
33 vs. 5 (p=0.04) 
ACA 
12 vs. 63 (p=<0.0001) 
ESR 
18 vs. 14 
(p=NS) 
CRP 
7.5 vs. 4 
(p=NS) 
  
Salliot et al, 
2006 
      Anti-Scl 70 
21.9 vs. 15.4 (p=0.66) 
ACA 
40.4 vs. 61.5        (p=0.09) 
Cryoglobulins 
5.3 vs. 20 
(p=0.09) 
   
Kobak et al, 
2013 
10.3 vs. 
32.5 
(p=0.048) 
5.1 vs. 15 
(p=0.576) 
19.2 vs. 
72.5 
(p=0.001) 
28.2 vs. 90 
(p<0.01) 
  Anti-Scl70 
55.1 vs. 92.5 (p=0.032) 
ACA 
26.9 vs. 80  
(p=0.001) 
   
Myositis vs. myositis/sSS patients 
Vancsa et al, 
2010 
8.5 vs. 11 5.4 vs. 11  25.4 vs. 44 10 vs. 0  Anti-U1-RNP  
2.3 vs. 0 
Anti Jo-1 
18.5 vs. 0 
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Figure 1: Flowchart of study selection 
Did not meet criteria based on 
abstract: 
(n=113) 
EMBASE (n=498)  PUBMED (n=1141) 
Total n= 1639 
Embase n=80 Pubmed n=70 
Total n=150 
Did not meet criteria based on title 
Pubmed (n=1071) Embase (n=418) 
Articles included in 
systematic review 
 
N=42 
Manually added after search n=5 
N= 37 
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Figure 2: Meta-analysis of the prevalence of sSS in SLE patients. 
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Figure 3: Meta-analysis of the prevalence of sSS in RA patients. 
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